PP1131
AXP000228.1 · Phage therapy
- Platform
- phage cocktail (12 phages)
- Originator
- Pherecydes Pharma
- Sponsor
- Phaxiam Therapeutics
Names
| Name | Type | Source |
|---|---|---|
| PP1131 | preferred name, code | curator, paper |
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- Pseudomonas aeruginosa bacteriophage (12-phage cocktail)
- Replication
- replicating
- Route
- topical
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (0)
No trial in the latest ClinicalTrials.gov snapshot names this program.
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 30292481 | Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. | The Lancet. Infectious diseases | 2019 | name in abstract: PP1131 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42617616 | Non-canonical phage-bacterium interactions during topical phage therapy in the PhagoBurn clinical trial: a retrospective, observational, reverse translational study. | The Lancet. Microbe | 2026 | name in abstract: PP1131 |
Notes
Cocktail of 12 natural lytic anti-Pseudomonas aeruginosa phages, applied to burn wounds in the PhagoBurn trial NCT02116010 (Jault 2019, Lancet Infect Dis). PhagoBurn also had an anti-E. coli arm whose product name is not given in the sources seen, so no program was created for it. Pherecydes Pharma merged with Erytech in 2023 to form Phaxiam Therapeutics.
How to cite
PP1131 (AXP000228.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000228.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.